Literature DB >> 20623079

3-Iodothyronamine (T(1)AM): a new chapter of thyroid hormone endocrinology?

Alexandra G Ianculescu1, Thomas S Scanlan.   

Abstract

3-Iodothyronamine (T(1)AM) is an endogenous thyroid hormone derivative with distinct biological effects that are largely opposite those of thyroid hormone. Administration of T(1)AM to rodents results in rapid and profound reduction in body temperature, heart rate, and metabolism. The structural similarities between thyroxine, T(1)AM, and monoamine neurotransmitters suggest an intriguing role for T(1)AM as both a neuromodulator and a hormone-like molecule that may constitute a part of thyroid hormone action. Several recent studies into its molecular mechanisms of action have shown that T(1)AM can target extracellular receptors such as the trace amine-associated receptors and the alpha(2A) adrenergic receptor, modulate the membrane transport of neurotransmitters, and serve as a substrate of specific membrane transport cellular uptake machinery. This review discusses recent T(1)AM studies, focusing on both the observed in vivo effects of T(1)AM administration and its actions at the molecular level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20623079     DOI: 10.1039/b926583j

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  10 in total

1.  Mitochondrial F(0) F(1) -ATP synthase is a molecular target of 3-iodothyronamine, an endogenous metabolite of thyroid hormone.

Authors:  S Cumero; F Fogolari; R Domenis; R Zucchi; I Mavelli; S Contessi
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  Effects of the thyroid hormone derivatives 3-iodothyronamine and thyronamine on rat liver oxidative capacity.

Authors:  P Venditti; G Napolitano; L Di Stefano; G Chiellini; R Zucchi; T S Scanlan; S Di Meo
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

3.  Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists.

Authors:  Gunnar Kleinau; Juliane Pratzka; Daniela Nürnberg; Annette Grüters; Dagmar Führer-Sakel; Heiko Krude; Josef Köhrle; Torsten Schöneberg; Heike Biebermann
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

Review 4.  The role of thyroid hormones as inductors of oxidative stress and neurodegeneration.

Authors:  I Villanueva; C Alva-Sánchez; J Pacheco-Rosado
Journal:  Oxid Med Cell Longev       Date:  2013-12-09       Impact factor: 6.543

Review 5.  Update on 3-iodothyronamine and its neurological and metabolic actions.

Authors:  Riccardo Zucchi; Alice Accorroni; Grazia Chiellini
Journal:  Front Physiol       Date:  2014-10-16       Impact factor: 4.566

6.  Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine.

Authors:  Ebru S Selen Alpergin; Zeinab Bolandnazar; Martina Sabatini; Michael Rogowski; Grazia Chiellini; Riccardo Zucchi; Fariba M Assadi-Porter
Journal:  Physiol Rep       Date:  2017-01

Review 7.  Neuroprotective mechanisms and translational potential of therapeutic hypothermia in the treatment of ischemic stroke.

Authors:  Jin Hwan Lee; James Zhang; Shan Ping Yu
Journal:  Neural Regen Res       Date:  2017-03       Impact factor: 5.135

8.  T1AM Attenuates the Hypoxia/Reoxygenation-Induced Necroptosis of H9C2 Cardiomyocytes via RIPK1/RIPK3 Pathway.

Authors:  Bo Wei; Hanbing Zhao; Bailong Hu; Lujun Dai; Guoning Zhang; Lili Mo; Niwen Huang; Changchao Zou; Bei Zhang; Haiyan Zhou; Wei Li; Xingde Liu
Journal:  Biomed Res Int       Date:  2022-02-28       Impact factor: 3.411

9.  NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T(1)AM treatment.

Authors:  J A Haviland; H Reiland; D E Butz; M Tonelli; W P Porter; R Zucchi; T S Scanlan; G Chiellini; F M Assadi-Porter
Journal:  Obesity (Silver Spring)       Date:  2013-05-29       Impact factor: 5.002

Review 10.  Thyroid Hormones, Thyromimetics and Their Metabolites in the Treatment of Liver Disease.

Authors:  Marta A Kowalik; Amedeo Columbano; Andrea Perra
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-10       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.